IP Library Granted Patent US 7,910,548
Granted Patent B2
US 7,910,548 · App. 08/870,762 · Granted Mar 22, 2011

Methods for treating obesity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,548
App. No.
08/870,762
Granted
Mar 22, 2011
Kind
B2
Abstract

Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent.

Claims (10)

1. A method of treating obesity in an obese human subject in need of said treatment consisting essentially of administering to said obese subject a therapeutically effective amount of pramlintide to decrease body weight after 4 four weeks of said treatment in said obese human subject from the body weight of said obese patient prior to said treatment, wherein said pramlintide in present in a composition comprising a pharmaceutically acceptable carrier, wherein from 0.5 to 2.0 mg/day of said pramlintide in said composition is administered to said obese subject from 1 to 4 times a day.

2. The method of claim 1 , wherein said composition is administered two times per day.

3. The method of claim 1 , wherein said composition is administered three times per day.

4. A method of treating obesity in an obese human subject in need of said treatment comprising administering to said obese subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an obesity-relief agent consisting of pramlintide to decrease body weight after 4 four weeks of said treatment in said obese human subject from the body weight of said obese patient prior to said treatment, wherein from 0.5 to 2.0 mg/day of said pramlintide in said composition is administered to said obese subject from 1 to 4 times a day.

5. The method of claim 4 , wherein said composition is administered three times per day.

6. A method of treating obesity in an obese human subject in need of said treatment comprising administering to said obese subject a therapeutically effective amount of pramlintide to decrease body weight after 4 four weeks of said treatment in said obese human subject from the body weight of said obese patient prior to said treatment, wherein said pramlintide is not administered in conjunction with another obesity-relief agent, wherein from 0.5 to 2.0 mg/day of said pramlintide is administered to said obese subject from 1 to 4 times a day.

7. A method of treating obesity in an obese human subject in need of said treatment comprising administering to said obese subject a therapeutically effective amount of a composition consisting essentially of pramlintide to decrease body weight after 4 four weeks of said treatment in said obese human subject from the body weight of said obese patient prior to said treatment, wherein from 0.5 to 2.0 mg/day of said pramlintide is administered to said obese subject from 1 to 4 times a day.

8. The method of claim 1 , 4 , 6 or 7 , wherein said pramlintide is pramlintide trifluoroacetate, pramlintide acetate, or pramlintide-HCl.

9. The method of claim 4 , 6 or 7 , wherein said composition is administered two times per day.

10. The method of claim 4 , 6 , or 7 , wherein said composition is administered three times per day.

Assignments (3)
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP Recorded Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →
CHANGE OF NAME Recorded Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2007
From: DUFT, BRADFORD J; KOLTERMAN, ORVILLE G
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 019498/0717 →